Visit to the UCL Cancer Institute

At the laboratory

As part of the TRACEPIGEN project, Dr Ivana Boljević spent two weeks in July on a short-stay secondment at UCL Cancer Institute, Department of Cancer Biology, Medical Genomics group (London, UK). She was hosted by Prof Stephan Beck and Dr Nnenna Kannu. During this period, she gained insights into the ongoing projects at the UCL, attended Medical Genomics laboratory meetings, and learned more about different bioinformatics pipelines, including the analysis of DNA methylation data. This short stay enabled her to gain exposure to an international environment and obtain additional transferable skills.

Like this article?

Leave a comment

Latest posts

Tanić et al. Nature Biotechnology 2022

M Tanić, I. Moghul, S. Rodney, P. Dhami, H. Vaikkinen, J. Ambrose, J. Barrett, A. Feber, S. Beck. Performance comparison and in-silico harmonisation of commercial platforms for DNA methylome analysis by targeted bisulfite sequencing. Nature Biotechnology 2022.

Cavic et al. Oncology, 2022

Cavic M, Kovacevic T, Zaric B, Stojiljkovic D, Jovanovic Korda N, Rancic M, Jankovic R, Radosavljevic D, Stojanovic G, Spasic J. Lung Cancer in Serbia. Journal of Thoracic Oncology. 2022, 17(7): 867-872.

Jokic et al. Expert Review of Anticancer Therapy, 2021

Jokic V, Savic-Vujovic K, Spasic J, Marinkovic M, Stanic N, Radosavljevic D, Cavic M. Hematological parameters in EGFR-mutated advanced NSCLC patients treated with TKIs: predicting survival and toxicity. Expert Review of Anticancer Therapy. 2021.

Marinkovic M et al. Biomed Research International, 2022

Marinkovic M, Popovic M, Stojanovic-Rundic S, Nikolic M, Cavic M, Gavrilovic D, Teodorovic D, Mitrovic D, Mijatovic Teodorovic Lj. Comparison of Different Machine Learning Models in Prediction of Postirradiation Recurrence in Prostate Carcinoma Patients. Biomed Research International. 2022, 2022:7943609.  

Jokic et al. Dose Response, 2022

Jokic V, Savic-Vujovic K, Spasic J, Bukumiric Z, Marinkovic M, Radosavljevic D, Cavic M. Evaluation of Clinical and Genetic Determinants of Treatment Outcome in EGFR Mutation Positive Advanced Lung Adenocarcinoma. Dose Response, 2022 Aug 4;20(3):15593258221117354. doi: 10.1177/15593258221117354.


Participation at the IASLC 2022 WCLC World Conference on Lung Cancer

TRACEPIGEN participant Milena Cavic attended the World Lung Cancer Congress (WCLC22) organized by the International Association for the Study of Lung Cancer (IASLC) in Vienna, Austria, August 5-9, 2022. WCLC22 is traditionally the world’s largest international gathering of clinicians, researchers and scientists in the field of lung cancer and thoracic oncology. The congress covered a

Scroll to Top